Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?Zacks Investment Research • 08/27/26
BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung DiseasePRNewsWire • 08/24/26
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri UptakeZacks Investment Research • 08/07/26
Insmed Catapults 30%, Leading A Biotech Rally; But Mirum Takes A BathInvestors Business Daily • 08/06/26
Insmed Reports Second-Quarter 2026 Financial Results and Provides Business UpdatePRNewsWire • 08/06/26
Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/30/26
Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026PRNewsWire • 07/23/26
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga • 07/21/26
Billionaire Investor Stanley Druckenmiller's Top 5 Picks: Worth Buying Today?24/7 Wall Street • 07/20/26
Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients TranscriptSeeking Alpha • 07/16/26